Formulary Monographs [VORICONAZOLE, 081408]
|
|
VORICONAZOLE
|
|
|
|
|
|
AZOLES
|
|
|
Invasive aspergillosis in immunocompromised patients; candidaemia, in non-neutropenic patients, fluconazole-resistant serious invasive candidiasis, oesophageal candidiasis, and serious fungal infections due to Scedosporium and Fusarium spp .
|
|
|
Visual disturbances, fever, rashes, nausea, vomiting, diarrhoea, abdominal pain, headache, sepsis, respiratory disorders, and peripheral oedema.
|
|
|
IV: adults and adolescents: 6 mg/kg every 12 hours for the first 24
hours followed by maintenance dose of 4 mg/kg twice daily ; a lower dose of 3 mg/kg twice daily may be suitable for candidaemia in non- neutropenic patients or for deep tissue C |
|
|
|
|
|
Because voriconazole can cause fetal harm, it should not be used during pregnancy except when benefits for the mother clearly outweigh potential risks for the fetus.
|
|
|
It is not known whether voriconazole is distributed into milk.
|
|
|
|